Crispr-Cas Systems: General Functional Aspects and Classification
=================================================================

The CRISPR ([c]{.ul}lustered [r]{.ul}egularly [i]{.ul}nterspaced [s]{.ul}hort [p]{.ul}alindromic [r]{.ul}epeats)-Cas (CRISPR-associated) systems are adaptive immune systems protecting prokaryotes against phages and other mobile genetic elements ([@B71]). These defensive systems are found in almost all sequenced archaeal and in about half of bacterial genomes ([@B24]). CRISPR-Cas systems are composed of CRISPR arrays and *cas* operons. CRISPR arrays in turn consist of short direct repeats (20--40 bp) separated by variable spacers. Some spacers are complementary to mobile genetic elements sequences ([@B68]). CRISPR arrays also contain leader regions carrying promoters from which their transcription initiates.

CRISPR-based defensive functions include two major processes: immunity (interference) and immunization (adaptation) (for general review, see [@B46]). CRISPR interference itself can be divided into two phases: the biogenesis of CRISPR RNAs and the targeting phase. At the first phase a CRISPR array is transcribed into a long RNA transcript (pre-crRNA), which is processed into small CRISPR RNAs (crRNAs), each consisting of one spacer and flanking repeat sequences. Individual crRNAs bind to Cas proteins forming a nucleoprotein effector complex, which is necessary for the second, targeting phase. The crRNAs serve as guides for recognizing nucleic acids by complementary base pairing. In this way, crRNAs direct recognition and, ultimately, cleavage of genetic elements by the Cas nucleases ([@B23]). Spacers are incorporated into CRISPR arrays in the process of adaptation ([@B31]). Cas1 and Cas2 proteins, found in almost all investigated CRISPR-Cas systems, are essential for this process ([@B34]). A very important aspect of CRISPR-based immunity is the ability to distinguish host DNA from the foreign one. Protospacer-adjacent motifs (PAMs) are short sequences situated on the 3′ or 5′ end of the protospacer (foreign DNA region corresponding to a CRISPR spacer) and required for protospacer recognition. PAMs are absent from CRISPR arrays, which prevents autoimmunity ([@B71]). PAMs are essential during spacer selection at the adaptation stage, which ensures that acquired spacers are functional in interference. Previous studies in type I CRISPR-Cas systems identified the sequence requirements for the CRISPR targeting that includes a perfect match between the 5′ end of the spacer and the protospacer within up to a 10-nt "seed" sequence ([@B65]; [@B79]; [@B40]).

CRISPR-Cas systems are highly diverse. This is reflected in both CRISPR array architectures and *cas* genes composition ([@B74]). The variability of *cas* gene sets has formed the basis of CRISPR-Cas systems classification ([@B43]). All investigated CRISPR-Cas systems are divided into two classes, characterized by the composition of *cas* genes involved in interference module ([@B34]). These classes in turn are divided into six types and 33 subtypes (see **Table [1](#T1){ref-type="table"}** for examples). The Class 1 comprises the most abundant and diverse type I and type III CRISPR-Cas systems as well as rare type IV. These types of CRISPR-Cas systems are found in both archaeal and bacterial genomes. Effector complexes of the type I and type III include Cas5, Cas7, Cas8 (in type I), and Cas10 (in type III) proteins ([@B34]). For crRNA processing Cas6 family proteins are necessary in these CRISPR-Cas systems ([@B18]). Type I systems are also characterized by the presence of Cas3 proteins responsible for degradation of DNA recognized by effector complexes ([@B15]). The Class 2 includes type II, type V and type VI CRISPR-Cas systems. These systems possess effector modules consisting of only one multi-domain protein. The most characterized is the type II Cas9 protein widely used in genome editing ([@B76]).

###### 

Main CRISPR-Cas systems subtypes and examples of system-harboring microorganisms and clostridial species.

  Class     Subtype   *cas* operon composition                                                                     Example                                                  Examples of clostridial species and strains
  --------- --------- -------------------------------------------------------------------------------------------- -------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Class 1   I-A       *cas6, cas11(csa5), cas7, cas5, cas8a1, cas3', cas3", cas2, cas4, cas1, cas4*                *Listeria monocytogenes* L99 ([@B66])                    *C. stercorarium* subsp. *stercorarium* DSM 8532 ([@B60]); *C. tetani* ATCC 9441 ([@B20])
            I-B       *cas6, cas8b1, cas7, cas5, cas3, cas4, cas1, cas2*                                           *Haloferax volcanii* H119 ([@B41])                       *C. difficile* 630, *C. difficile* R20291 ([@B13]); *C. pasteurianum* BC1 ([@B61]); *C. acetobutylicum* GXAS18-1 ([@B58]); *C. tetani* ATCC 9441 ([@B20])
            I-C       *cas3, cas5, cas8c, cas7, cas4, cas1, cas2*                                                  *Desulfovibrio vulgaris* str. *Hildenborough* ([@B27])   *C. cellulolyticum* H10 ([@B16])
            I-U       *cas3, cas8u2, cas7, cas5-cas6, cas4-cas1, cas2*                                             *Geobacter sulfurreducens* ([@B34])                      --
            I-D       *cas3', cas3", cas10d, cas7(csc2), cas5(csc1), cas6, cas4, cas1, cas2*                       *Cyanothece* sp. 8802 ([@B34])                           --
            I-E       *cas3, cas8e(cse1), cas11(cse2), cas7, cas5, cas6, cas1, cas2*                               *Escherichia coli* K12 ([@B34])                          --
            I-F       *cas1, cas2-cas3, cas8f(csy1), cas5(csy2), cas7(csy3), cas6f*                                *Pseudomonas aeruginosa* PA14 ([@B79])                   --
            III-A     *cas6, cas10, cas11(csm2), cas7(csm3), cas5(csm4), cas7(csm5), csm6, cas1, cas2*             *Staphylococcus epidermidis* ([@B34])                    *C. tetani* ATCC 453 ([@B20])
            III-B     *cas7(cmr1), cas10, cas5(cmr3), cas7(cmr4), cas11(cmr5), cas6, cas7(cmr6*)                   *Pyrococcus furiosus* ([@B34])                           *C. botulinum* ATCC 3502 ([@B52])
            III-C     *cas7(cmr1), cas7(cmr6), cas10, cas7(cmr4), cas11(cmr5), cas5(cmr3)*                         *Methanothermobacter thermautotrophicus* ([@B34])        --
            III-D     *cas10, cas7(csm3), cas5(csx10), cas11(csm2), cas7(csm7), cas7(csm5), all1473, cas7(csm5)*   *Synechocystis sp.* 6803 ([@B44])                        --
  Class 2   II-A      *cas9, cas1, cas2, csn2*                                                                     *Enterococcus faecalis* OG1RF ([@B14])                   --
            II-B      *cas9, cas1, cas2, cas4*                                                                     *Legionella pneumophila* str. *Paris* ([@B34])           --
            II-C      *cas9, cas1, cas2*                                                                           *Neisseria lactamica* 020-06 ([@B34])                    *C. perfringens* JGS1495 ([@B57])
            V-A       *cas12a(cpf1), cas4, cas1, cas2*                                                             *Francisella cf. novicida* Fx1 ([@B34])                  --
            V-B       *cas12b(c2c1), cas4, cas1, cas2*                                                             *Alicyclobacillus acidoterrestris* ([@B34])              --
            V-C       *cas1, cas12c(c2c3)*                                                                         *Oleiphilus* sp. ([@B34])                                --
            V-D       *cas1, cas12d(casY)*                                                                         *Bacterium* CG09_39_24 ([@B34])                          --
            V-E       *cas12e(casX), cas4, cas1, cas2*                                                             *Deltaproteobacteria bacterium* ([@B34])                 --
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The type I CRISPR-Cas systems are highly diverse and subdivided into seven subtypes (I-A, I-B, I-C, I-U, I-D, I-E, I-F) ([@B44]). The subtypes I-C, I-D, I-E, I-F are encoded by a single operon in CRISPR loci, whereas subtype I-A and I-B are often encoded by several operons. I-C, I-E, and I-F subtypes are mostly present in bacteria, while I-A, I-B, and I-D are common in archaea ([@B43]) (**Table [1](#T1){ref-type="table"}**). The subtype I-B, characterized by a specific Cas8b protein, is present in methanogenic and halophilic archaea and in clostridia. Studies of the I-B CRISPR-Cas systems in haloarchaea showed some interesting features such as multiple PAMs and 9-nucleotide non-contiguous seed region ([@B39]). Although the subtype I-B was found in clostridial species it has not been well studied there yet. It is suggested that I-B CRISPR-Cas system possibly had been acquired by clostridia from archaea via horizontal gene transfer and afterward evolved independently ([@B58]). Other CRISPR-Cas systems subtypes, including I-A, I-C, III-A, III-B, and II-C, are also present in some clostridial species (**Table [1](#T1){ref-type="table"}**).

Characterization of *Clostridium difficile* Crispr-Cas System
=============================================================

*Clostridium difficile* (novel name *Clostridioides difficile*) is an anaerobic spore-forming bacterium, one of the major clostridial pathogens and the major cause of nosocomial infections associated with antibiotic therapy ([@B2]). During its infection cycle, this enteropathogen must cope with the presence of foreign DNA elements, including bacteriophages, in the crowded environment of the gut, and is thus expected to rely on efficient defense systems such as CRISPR-Cas to control genetic exchanges favored in its complex niche.

The first evidence suggesting the presence of active CRISPR-Cas system in *C. difficile* was obtained during deep-sequencing of regulatory RNAs in *C. difficile* ([@B72]). This study revealed abundant and diverse crRNAs. Active expression and processing of CRISPR loci was detected in this and a subsequent study ([@B72]; [@B13]).

Bioinformatics analysis of more than 200 *C. difficile* genomes ([@B26]; [@B4]) demonstrated that *C. difficile* CRISPR-Cas system belongs to I-B subtype ([@B34]). *C. difficile* CRISPR-Cas system possesses several original features (**Figure [1](#F1){ref-type="fig"}**). CRISPR-Cas system of this enteropathogen is characterized by an unusual large set of CRISPR arrays. For example, reference 630 and hypervirulent R20291 *C. difficile* strains contain 12 and 9 CRISPR arrays, respectively ([@B72]; [@B13]). These CRISPR arrays are orientated in the direction of chromosome replication, as observed for highly expressed bacterial genes and presumably ensuring their optimal transcription ([@B5]; [@B13]). On average, known *C. difficile* genomes contain 8.5 arrays ([@B4]). In most sequenced *C. difficile* strains several CRISPR arrays are located in prophages ([@B26]; [@B13]). The crRNAs originating from arrays located in prophages were found to be the most expressed in 630 and R20291 strains. Prophage localization of actively expressed CRISPR arrays may play a role in preventing infection by related competing phages by targeting their DNA ([@B70]).

![Schematic view of the chromosomal location of CRISPR arrays and the organization of the *cas* operons in *C. difficile* strains 630 **(A)** and R20291 **(B)**. CRISPR arrays (CR) are numbered according to the CRISPRdb database ([@B24]). Arrowheads signify arrays' position and transcriptional orientation. The locations of associated *cas* operons, prophage regions, toxin-antitoxin pairs (TA) or only antitoxins (A) and replication origin (ori) are indicated. The organization of the *cas* operons in strain 630 (left) and R20291 (right) are indicated with roman numerals, where i -- full operons; ii -- partial operons, iii -- an additional operon. Functional modules are marked with braces. The same color was used for homologous *cas* genes ([@B13]).](fmicb-09-01740-g001){#F1}

Another unusual feature of *C. difficile* CRISPR-Cas system is the presence of two or three (in 027 ribotype strains) *cas* gene sets in the majority of sequenced strains ([@B13]) (**Figure [1](#F1){ref-type="fig"}**). The full *cas* operon encodes all necessary genes for CRISPR interference (*cas6, cas8b, cas7, cas5, cas3*) as well as *cas1*, *cas2*, *cas4* genes essential for spacer acquisition ([@B3]; [@B32]; [@B37]). The additional *cas* operons lack the adaptation module. While the complete *cas* gene operons were found in ∼90% of sequenced *C. difficile* strains, the additional partial *cas* gene sets are present in almost all strains ([@B13]). Thus, some *C. difficile* strains could have lost the ability to adapt to new genetic elements through their CRISPR-Cas systems. The *cas* operon occurrence correlates with evolutionary relationships of *C. difficile* strains reflecting their epidemiological context and, possibly, the intensity of interactions with foreign DNA elements ([@B13]). When present, complete *cas* gene operons are usually associated with longest CRISPR arrays, which is indicative of active new spacer acquisition (or slower spacer loss) and hints to an existence of some still unknown *in cis* mechanisms responsible for different dynamics of *cas* proximal arrays. The conservation of CRISPR array structure and sequences of all CRISPR repeats in *C. difficile* genomes suggests that CRISPR arrays located far from *cas* operons use the same set of Cas proteins for their function.

An interesting evolutionary aspect of *C. difficile* CRISPR-Cas system has been recently reported ([@B42]). Analysis of about 2,500 *C. difficile* genomes revealed co-localization of type I toxin-antitoxin (TA) modules with CRISPR arrays (**Figure [1](#F1){ref-type="fig"}**). TA -- CRISPR array co-localization has never been reported for other bacteria and its significance remains unclear. CRISPR-arrays localized in prophage regions are in particular prone to be associated with type I TA modules, which may contribute to the stabilization of these chromosomal regions by the mechanism similar to plasmid maintenance through post-segregation killing.

The function of CRISPR-Cas system is to provide defense against viruses and other mobile genetic elements. Recent bioinformatics analysis of *C. difficile* CRISPR spacers matching known sequences showed that most of them target clostridial phages and prophage regions ([@B26]; [@B13]). This suggests that this entheropathogen actively interacts with phages, and that CRISPR-Cas actively modulates this interaction. Identification of protospacers allowed to deduce PAM sequences. While 3-nucleotide 5′-motifs CCA or CCT were most common, alternative sequences CCC, CCG, and TCA were also frequently found. Multiple PAMs were also observed in other type I-B systems ([@B67]). Conjugation efficiency experiments with plasmid vectors containing CCA and CCT PAMs and protospacers corresponding to the first spacers from actively expressed *C. difficile* 630 CRISPR arrays showed active CRISPR interference in *C. difficile* cells thus validating bioinformatically predicted PAMs and showing that *C. difficile* CRISPR-Cas system is naturally capable of defensive function ([@B13]). Phage infection assays in 630 and R20291 strains revealed the correlation between the presence of CRISPR spacer-targeting phage sequences and phage susceptibility. Experiments using a heterologous *E. coli* host system showed that both *cas* operons of *C. difficile* 630 strain are capable of interference.

Regulation and Potential Alternative Functions of *C. difficile* Crispr-Cas System
==================================================================================

During its infection cycle *C. difficile* faces with different stress conditions and changing environments inside the host. To survive in phage-rich gut community while relying on the CRISPR-Cas defense, *C. difficile* needs to regulate CRISPR-Cas expression in response to different environmental signals. A study by [@B13] revealed that all the CRISPR arrays and *cas* genes are expressed under standard laboratory conditions. The level of CRISPR-Cas expression could be modulated by specific regulatory mechanisms.

Bacterial pathogens often form biofilms, which help them resist different threats inside the host. It was shown that *C. difficile* actively forms biofilms ([@B22]; [@B51]; [@B69]) during its infection cycle. Biofilm conditions are characterized by high cell densities, which increase the possibility of horizontal gene transfer ([@B6]; [@B1]). Quorum sensing is one of bacterial mechanisms that regulates gene expression depending on the density of the population ([@B49]). Recent studies showed that *cas* gene expression is induced by quorum sensing signals in *Serratia sp.* (I-E, I-F, and III-A subtypes) ([@B56]) and *Pseudomonas aeruginosa* (I-F subtype) ([@B29]). Moreover, CRISPR-Cas systems may play a role in biofilm formation and colonization of the host. For instance, CRISPR-Cas (II-A subtype) harboring *Enterococcus faecalis* strain has increased biofilm formation ([@B14]). Furthermore, CRISPR-Cas-mediated gene regulation of the ability to swarm and form biofilms was revealed in *P. aeruginosa* ([@B80]). In *C. difficile* strain 630, a recent study revealed up to 20-fold induction of *cas* genes expression in biofilms ([@B42]), suggesting the regulation of *C. difficile* CRISPR-Cas system activity by biofilm-related factors. During infection, the complex interactions with different microbiota members within gut communities should be considered. More studies are thus needed to assess the possible link between biofilm-related signals and the regulation of CRISPR-Cas expression during the *C. difficile* infection cycle.

The obvious stress to induce CRISPR-Cas system is phage infection. At the earliest stages of attachment to the cell surface, it is often accompanied by the envelope stress ([@B62]). The induction of the CRISPR-Cas system expression in response to this type of stress was found in different bacteria ([@B78]). Bacterial pathogens and commensals always combat with the host's immune response, which results in a wide range of stressful effects. Several studies reported the changes of *cas* gene transcription in *Desulfovibrio vulgaris* ([@B50]), *Streptococcus sanguinis* ([@B63]), *Pasteurella multocida* ([@B48]), and *Lactobacillus rhamnosus* ([@B35]) in response to different stresses such as changes in growth rate, bile, oxidative, nitrosative stresses and exposure to antibiotics. Virulence is a specific response of pathogens to different stress factors inside the host ([@B38]). The regulation of CRISPR-Cas systems during the infection cycle may indicate an important role of these systems in pathogens. Recently, a role of an alternative SigB factor in stress response was investigated in *C. difficile* ([@B33]). Interestingly, SigB-dependent promoters were found upstream of both *cas* operons in *C. difficile* strain 630 ([@B42]) and fivefold decrease in expression levels of both *cas* operons was observed in *sigB* mutant strain. This suggests regulation of *C. difficile* CRISPR-Cas system via stress-related signals and a potential role of this system in the survival of *C. difficile* inside the host.

Besides the adaptive immunity, multiple alternative functions of CRISPR-Cas systems have been revealed ([@B38]; [@B78]). These functions occur through targeting bacterium' own genes by partially or fully matching crRNAs. For instance, in *Listeria monocytogenes* a specific long type I-A CRISPR array transcript *rliB* processed by polynucleotide phosphorylase (PNPase) controls the expression of the *feoAB* genes important for virulence ([@B45]; [@B66]). An *rliB* mutant colonizes its host more effectively than the wild type strain. Bioinformatics analysis of *C. difficile* CRISPR spacers showed that all investigated strains carry genome-targeting spacers ([@B13]). It may thus be speculated that *C. difficile* CRISPR-Cas system might also have functions in the regulation of the endogenous gene expression. The possible role of CRISPR-Cas systems in genome evolution via self-targeting is actively discussed ([@B78]).

Potential Applications of *C. difficile* Crispr-Cas System
==========================================================

During the last decade, discoveries in the CRISPR field led to rapid development of revolutionary biotechnological applications especially in genome editing by CRISPR-Cas9 technology ([@B30]). Different CRISPR-based tools have proved to be effective both in prokaryotes and eukaryotes ([@B30]; [@B9]).

Since spacers are acquired in an orderly manner, with more recently acquired spacer being closer to the leader sequence ([@B8]; [@B54]) the order of spacers within an array reflects phage invasions in different populations of the same bacterial species. This feature can reveal phylogenetic relations between strains and can be used in genotyping techniques ([@B38]; [@B4]). Such "CRISPR-typing" has been already applied for outbreak tracking of *Yersinia pestis* ([@B21]; [@B10]) and *Salmonella enterica* ([@B75]; [@B59]). Moreover, CRISPR typing is capable to reveal antibiotic-resistant phenotypes ([@B55]) or prophages ([@B53]). These correlations can be explained by the influence of active CRISPR-Cas systems on the horizontal gene transfer, which plays important role in the acquisition of new genes and operons, essential for bacterial pathogenesis and adaptation ([@B38]). CRISPR-typing approach based on spacer content and polymorphism can be successfully applied to *C. difficile* with correlation between CRISPR-groups and toxin groups ([@B4]).

CRISPR-Cas systems can be applied for development of new antimicrobials based on the self-targeting ([@B12]). The general strategy is the use of phage particles and phagemids as vectors to deliver auto-targeting CRISPR-Cas components inside a pathogenic cell ([@B11]). Many pathogens possess endogenous active CRISPR-Cas systems, which can be repurposed for self-targeting. Since *C. difficile* contains a naturally active CRISPR-Cas system, such a strategy could be promising for control and even treatment of *C. difficile* infection (CDI), in the context of recent worldwide emergence of antibiotic-resistant *C. difficile* strains ([@B7]). Phage therapy of CDI has proved to be another promising alternative, but it faces some difficulties including lack of appropriate phages ([@B25]; [@B64]). The presence of active CRISPR-Cas system should effectively prevent infection by at least some phages complicating matters further.

The most popular biotechnological application of CRISPR-Cas systems is genome editing ([@B9]). In prokaryotes, the most interesting is the application of endogenous CRISPR-Cas systems since it requires the introduction of less additional components for the editing process. Several works showing the applications of endogenous I-B subtype systems for genome editing were recently published. The first one, by [@B61] describes this approach in *Clostridium pasteurianum*. In this study, a plasmid vector containing an artificial CRISPR array with a protospacer targeting the gene of interest and arms for homologous recombination was used to delete the *cpaAIR* gene encoding a restriction enzyme ([@B61]). This approach allows fast and markless deletion or modification of the genes of interest in bacteria. Later, other studies confirmed the efficiency of this method in other I-B subtype-carrying organisms: archaeon *Haloarcula hispanica* ([@B19]) and butanol producing *Clostridium tyrobutyricum* ([@B81]). Another study revealed that *Haloferax volcanii* CRISPR-Cas system with deletions of *cas3* and *cas6* genes can be used for programmable repression of genes in this archaeon ([@B73]). Many efficient approaches for *C. difficile* genome manipulation exist to date. ClosTron is a method based on altered type II intron, which is able to insert in almost every region of the chromosome ([@B36]). Another method is CodA allele exchange technique based on semi-suicidal vector carrying the *E. coli codA* gene as a counter-selectable marker ([@B17]). Successful application of CRISPR-Cas9 ([@B47]; [@B77]) and Cpf1 ([@B28]) systems for genome editing in *C. difficile* was recently reported and may further extend our ability to manipulate the genome of this pathogen.

Despite the recent insights, many aspects of *C. difficile* CRISPR-Cas system remain to be characterized. We hope that future studies will shed new light on the secrets of *C. difficile* success within host environments relying on effective defense systems and will lead to promising medical and biotechnological applications.
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